According to AVEO Oncology 's latest financial reports the company's total debt is NZ$63.47 Million. A companyโs total debt is the sum of all current and non-current debts.
Year | Total debt | Change |
---|---|---|
2021-12-31 | NZ$55.59 M | 177.07% |
2020-12-31 | NZ$20.06 M | -14.29% |
2019-12-31 | NZ$23.4 M | -17.5% |
2018-12-31 | NZ$28.37 M | 9.06% |
2017-12-31 | NZ$26.01 M | 28.7% |
2016-12-31 | NZ$20.21 M | 46.09% |
2015-12-31 | NZ$13.83 M | -47.5% |
2014-12-31 | NZ$26.35 M | 12.78% |
2013-12-31 | NZ$23.37 M | -26.16% |
2012-12-31 | NZ$31.65 M | 2.2% |
2011-12-31 | NZ$30.96 M | 2.09% |
2010-12-31 | NZ$30.33 M | 11.58% |
2009-12-31 | NZ$27.18 M | -25.08% |
2008-12-31 | NZ$36.28 M | 84.32% |
2007-12-31 | NZ$19.68 M |
Company | Total debt/th> | differencediff. | Country |
---|---|---|---|
![]() Biogen BIIB | NZ$10.86 B | 17,017.89% | ๐บ๐ธ USA |
![]() Regeneron Pharmaceuticals REGN | NZ$4.43 B | 6,892.76% | ๐บ๐ธ USA |
![]() Merrimack Pharmaceuticals MACK | NZ$27.23 M | -57.09% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | NZ$84.08 B | 132,368.98% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | NZ$63.20 B | 99,475.75% | ๐บ๐ธ USA |
![]() Amgen AMGN | NZ$94.16 B | 148,247.98% | ๐บ๐ธ USA |